A “standout” 2025 propelled by a resurgence in mergers and acquisitions (M&A) has put RTW Biotech Opportunities (RTW) in a bullish mood about prospects for further returns. Fund manager Roderick Wong said biotechnology was “entering a new phase of maturity” with scientific breakthroughs enabling the emergence of a new cadre of profitable $50bn market leaders. … Continue reading RTW Biotech says prospects are “compelling” as drug developers begin “a new phase of maturity”